Your browser doesn't support javascript.
High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection.
Jacobsen, Eva-Maria; Fabricius, Dorit; Class, Magdalena; Topfstedt, Fernando; Lorenzetti, Raquel; Janowska, Iga; Schmidt, Franziska; Staniek, Julian; Zernickel, Maria; Stamminger, Thomas; Dietz, Andrea N; Zellmer, Angela; Hecht, Manuel; Rauch, Peter; Blum, Carmen; Ludwig, Carolin; Jahrsdörfer, Bernd; Schrezenmeier, Hubert; Heeg, Maximilian; Mayer, Benjamin; Seidel, Alina; Groß, Rüdiger; Münch, Jan; Kirchhoff, Frank; Bode, Sebastian F N; Strauss, Gudrun; Renk, Hanna; Elling, Roland; Stich, Maximillian; Voll, Reinhard E; Tönshof, Burkhard; Franz, Axel R; Henneke, Philipp; Debatin, Klaus-Michael; Rizzi, Marta; Janda, Ales.
  • Jacobsen EM; Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Ulm, Germany.
  • Fabricius D; Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Ulm, Germany.
  • Class M; Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Ulm, Germany.
  • Topfstedt F; Department of Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Lorenzetti R; Department of Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Janowska I; Department of Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Schmidt F; Department of Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Staniek J; Department of Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Zernickel M; Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Ulm, Germany.
  • Stamminger T; Institute of Virology, Ulm University Medical Center, Ulm, Germany.
  • Dietz AN; Institute of Virology, Ulm University Medical Center, Ulm, Germany.
  • Zellmer A; CANDOR Bioscience GmbH, Wangen im Allgäu, Germany.
  • Hecht M; CANDOR Bioscience GmbH, Wangen im Allgäu, Germany.
  • Rauch P; CANDOR Bioscience GmbH, Wangen im Allgäu, Germany.
  • Blum C; Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Ulm, Germany.
  • Ludwig C; Department of Transfusion Medicine, Ulm University, Ulm, Germany.
  • Jahrsdörfer B; Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg - Hessen and University Hospital Ulm, Ulm, Germany.
  • Schrezenmeier H; Department of Transfusion Medicine, Ulm University, Ulm, Germany.
  • Heeg M; Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg - Hessen and University Hospital Ulm, Ulm, Germany.
  • Mayer B; Department of Transfusion Medicine, Ulm University, Ulm, Germany.
  • Seidel A; Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg - Hessen and University Hospital Ulm, Ulm, Germany.
  • Groß R; Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Münch J; Department of Statistics, University of Ulm, Ulm, Germany.
  • Kirchhoff F; Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
  • Bode SFN; Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
  • Strauss G; Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
  • Renk H; Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
  • Elling R; Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Ulm, Germany.
  • Stich M; Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Ulm, Germany.
  • Voll RE; University Children's Hospital Tuebingen, Tuebingen, Germany.
  • Tönshof B; Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Franz AR; Center for Pediatrics and Adolescent Medicine, Medical Center, Faculty for Medicine, University of Freiburg, Freiburg, Germany.
  • Henneke P; Department of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.
  • Debatin KM; Department of Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Rizzi M; Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Janda A; Department of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.
Nat Commun ; 13(1): 7315, 2022 Nov 28.
Article in English | MEDLINE | ID: covidwho-2133436
ABSTRACT
The COVID-19 course and immunity differ in children and adults. We analyzed immune response dynamics in 28 families up to 12 months after mild or asymptomatic infection. Unlike adults, the initial response is plasmablast-driven in children. Four months after infection, children show an enhanced specific antibody response and lower but detectable spike 1 protein (S1)-specific B and T cell responses than their parents. While specific antibodies decline, neutralizing antibody activity and breadth increase in both groups. The frequencies of S1-specific B and T cell responses remain stable. However, in children, one year after infection, an increase in the S1-specific IgA class switch and the expression of CD27 on S1-specific B cells and T cell maturation are observed. These results, together with the enhanced neutralizing potential and breadth of the specific antibodies, suggest a progressive maturation of the S1-specific immune response. Hence, the immune response in children persists over 12 months but dynamically changes in quality, with progressive neutralizing, breadth, and memory maturation. This implies a benefit for booster vaccination in children to consolidate memory formation.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Child / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-35055-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Child / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-35055-1